Full history for every metric is available with a Kvantra account

Stock profile
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
23.2
History
P/E NTM
9.0
Market cap
10.41B
Currency USD
KvantraRankAbout79
IValue57
IIQuality97
IIIMomentum88
Current price
91.35 USD-1.82%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m2684436608291,0151,3971,8021,983
Operating profit$m8031,008
Net profit$m1294032022824443174851,070
EPS reported$2.563.93
Operating cashflow per share$5.447.89
Capex per share$0.060.11
FCF per share$5.387.78
Free cash flow$m645886
Net debt$m2,0002,176
Book value equity$m48.8-55.2
Book value per share$0.39-0.45
Number of sharesm123.9122.61
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx26.2923.24
P/B LTMx165.22-188.54
P/S LTMx5.775.78
P/FCF LTMx12.5111.76
EV/EBITDA LTMx17.5815.63
EV/Sales LTMx7.216.99
Earnings Yield LTM%3.80%4.30%
FCF Yield%7.99%8.51%
Quality
ROE%649.18%544.26%
ROIC%23.20%22.61%
Operating margin%57.47%55.91%
Gross margin%83.62%82.27%
FCF/Sales%46.15%49.15%
Growth and momentum
EPS Growth YoY%-25.36%-17.26%
Sales Growth YoY%+37.55%+45.03%
Net Income Growth YoY%-28.64%-18.48%
FCF Growth%+37.62%+47.06%
Operating Profit Growth%+45.54%+36.67%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx0.300.27
Net Debt/EBITDAx3.512.76
EBIT/Net interestx44.2845.70
Net debt/market cap%24.80%20.89%
Net debt/Equityx40.97-39.39
Gross debt/equityx43.89-58.84

ETFs that hold Halozyme Therapeutics

FundTickerPosition#Weight
Schwab U.S. Small-Cap ETFSCHA50.28%
iShares Ageing Population UCITS ETFAGED.L60.68%
Invesco S&P MidCap 400 GARP ETFGRPM52.61%
Congress SMID Growth ETFCSMD23.49%
Invesco S&P MidCap 400 Pure Growth ETFRFG12.81%
Nomura Small and Mid Cap ETFSMDC51.74%

Funds with Halozyme Therapeutics among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price91.35 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Halozyme Therapeutics, Inc. (HALO)

HALO · NASDAQ · Healthcare
91.35 USD-1.82%
Sign up to track this stock
Benchmarks
KvantraRank79
Market cap10.41B
P/E NTM9.0
P/E TTM23.2
KvantraRank?79 / 100
Value
57
Quality
97
Momentum
88
Financialsin USD
20242025TTM2026E
ETFs that hold Halozyme Therapeutics
FundTickerPosition#Weight
Schwab U.S. Small-Cap ETFSCHA50.28%
iShares Ageing Population UCITS ETFAGED.L60.68%
Invesco S&P MidCap 400 GARP ETFGRPM52.61%
Congress SMID Growth ETFCSMD23.49%
Invesco S&P MidCap 400 Pure Growth ETFRFG12.81%
Nomura Small and Mid Cap ETFSMDC51.74%

Funds with Halozyme Therapeutics among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current91.35 USD
Upside
Price consensus
Last year average price target
Current price91.35 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free